The Ensign Group, Inc.

  • Market Cap: Small Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US29358P1012
USD
175.36
-1.73 (-0.98%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryCompany CV
About The Ensign Group, Inc. stock-summary
stock-summary
The Ensign Group, Inc.
Pharmaceuticals & Biotechnology
Ensign Group, Inc., through its operating subsidiaries, provides healthcare services. The Company's operating subsidiaries provide a spectrum of skilled nursing services, physical, occupational and speech therapies and other rehabilitative and healthcare services. The Company operates approximately 231 healthcare operations, 24 of which also include assisted living operations across thirteen states. It operates the healthcare facilities across Arizona, California, Colorado, Idaho, Iowa, Kansas, Nebraska, Nevada, South Carolina, Texas, Utah, Washington and Wisconsin. Through its skilled nursing operations, the Company provides short stay patients and long stay patients with a range of medical, nursing, rehabilitative, pharmacy and routine services, including daily dietary, social and recreational services.
Company Coordinates stock-summary
Company Details
29222 Rancho Viejo Rd Ste 127 , SAN JUAN CAPISTRANO CA : 92675-1049
stock-summary
Tel: 1 949 4879500
stock-summary
Registrar Details
stock-recommendation Shareholding
Shareholding Snapshotstock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 119 Schemes (55.75%)

Foreign Institutions

Held by 164 Foreign Institutions (9.04%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summary Board of Directorsstock-summary
Management
Designation
Mr. Christopher Christensen
Co-Founder, Executive Chairman and the Chairman of the Board
Mr. Roy Christensen
Chairman Emeritus
Mr. Barry Port
Chief Executive Officer, Director
Ms. Swati Abbott
Independent Director
Dr. Ann Blouin
Independent Director
Mr. Lee Daniels
Independent Director
Mr. Daren Shaw
Independent Director
stock-recommendation Stock DNA
Revenue and Profits:
Net Sales:
1,228 Million
(Quarterly Results - Jun 2025)
Net Profit:
84 Million
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 10,536 Million (Small Cap)

stock-summary
P/E

30.00

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.13%

stock-summary
Debt Equity

-0.08

stock-summary
Return on Equity

16.09%

stock-summary
Price to Book

5.22